What is emphysema, including its pathophysiology, clinical presentation, and management?

Emphysema: Definition, Pathophysiology, Clinical Presentation, and Management

Emphysema is a permanent, destructive enlargement of airspaces distal to the terminal bronchioles without obvious fibrosis, resulting in loss of lung elastic recoil and progressive airflow limitation that is largely irreversible. 1

Pathophysiology

Anatomical Definition and Structural Changes

Emphysema causes permanent destruction of alveolar walls and airspaces, distinguishing it from reversible airway diseases 1. The key pathophysiological mechanisms include:

• Loss of pulmonary elastic recoil is the primary driver of airflow limitation, causing lungs to operate at higher volumes at any given pleural pressure 2
• Loss of alveolar attachments to bronchiolar walls contributes to airway collapse during expiration, as the normal tethering effect that keeps small airways open is destroyed 1
• Altered pressure relationships between pleura and alveoli facilitate expiratory dynamic compression of airways, limiting airflow during forced and even tidal expiration in severe cases 2

Emphysema Subtypes

Three distinct anatomical patterns exist with different functional consequences 1:

• Centriacinar (centrilobular) emphysema: Destroys respiratory bronchioles, alveolar ducts, and central acinar alveoli while peripheral alveoli remain intact; most commonly associated with smoking; involves more small airways disease and less elastic recoil loss for any given level of dysfunction 1
• Panacinar emphysema: Involves uniform destruction of the entire acinus; associated with alpha-1 antitrypsin deficiency; causes earlier and more pronounced loss of elastic recoil 1, 3
• Paraseptal emphysema: Affects areas adjacent to connective tissue septa; predisposes to pneumothorax and bullae formation 1

Inflammatory Mechanisms

Cigarette smoke triggers an inflammatory cascade that drives emphysema progression 1:

• Mononuclear cells (macrophages, lymphocytes) predominate in airway mucosa 1
• Neutrophils accumulate in airway fluid 1
• Eosinophils may contribute in some patients 1
• Protease-antiprotease imbalance is the central mechanism, with smoke overwhelming protective antiproteinase defenses 3
• Recent evidence shows CD207-positive dendritic cells promote emphysema progression through CD8+ T cell activation and MHC-I antigen cross-presentation 4

Functional Consequences

The structural damage produces characteristic physiological derangements 1:

• Decreased maximum expiratory flow and slow forced lung emptying 1
• Increased total lung capacity and residual volume due to air trapping 1
• Severely reduced diffusing capacity (DLCO) from loss of alveolar surface area, typically 35-45% predicted 2, 5
• Ventilation-perfusion (V/Q) mismatch is the major mechanism of hypoxemia at all disease stages 1
• Preserved or near-normal spirometric volumes may mask severe functional impairment, particularly in combined pulmonary fibrosis and emphysema (CPFE) 5

Disease Progression

Most new emphysema arises from mechanically affected lung (MAL) adjacent to existing emphysema rather than from small airway disease 6:

• High MAL regions contribute 60.5% of new emphysema 6
• Intermediate MAL contributes 37.1% 6
• Small airway disease contributes only 4.8% 6
• Higher MAL is associated with faster FEV1 decline (-2.2 ml/yr) and increased mortality 6

Clinical Presentation

Symptoms

Dyspnea is the cardinal symptom, present in >95% of patients, often disproportionate to spirometric findings 5:

• Progressive exertional breathlessness that worsens over months to years 1
• Chronic cough in 30-70% of patients 5
• Exercise-induced oxygen desaturation is frequent and correlates with pulmonary hypertension 5
• Substantial proportion of patients with severe emphysema may be asymptomatic, leading to late diagnosis 3

Physical Examination Findings

Physical findings are not specific for emphysema 2:

• Barrel chest deformity from hyperinflation
• Decreased breath sounds
• Prolonged expiratory phase
• Use of accessory respiratory muscles
• Pursed-lip breathing

Risk Factors and Epidemiology

Cigarette smoking is the dominant risk factor 1:

• 90% of CPFE patients report >40 pack-years smoking history 5

• Occupational exposures contribute in some cases 1
• Alpha-1 antitrypsin deficiency causes early-onset panacinar emphysema 3
• Predominantly affects males aged 65-70 years 5
• Often diagnosed late because patients lack symptoms even at low FEV1 1

Diagnostic Approach

Spirometry

Spirometry is essential for diagnosis but may underestimate disease severity 1:

• FEV1 <80% predicted and FEV1/FVC <0.7 defines airflow obstruction 1
• Minimal reversibility with bronchodilators distinguishes emphysema from asthma 1
• Preserved FVC and TLC may mask severe disease, particularly in CPFE 5

Diffusing Capacity

DLCO is severely reduced and helps distinguish emphysema from other causes of airflow obstruction 1, 5:

• Typically 35-45% predicted in emphysema 5
• More severely reduced than in chronic bronchitis or asthma 1
• Correlates with extent of alveolar destruction 2

Imaging

High-resolution CT (HRCT) is the gold standard for identifying emphysema pattern and severity 1, 5:

• Evidence of emphysema on imaging favors COPD over asthma 1
• CT reporting quality is highly variable in clinical practice, with only 26% of reports including phenotype, severity, and location 7
• Radiologic changes are less sensitive than physiologic measurements 2

Differential Diagnosis

Distinguishing emphysema from chronic asthma in older patients is the most challenging diagnostic problem 1:

Features favoring emphysema:

• Heavy smoking history 1
• Evidence of emphysema on HRCT 1
• Decreased diffusing capacity 1
• Chronic hypoxemia 1

Features favoring asthma:

• Atopy 1
• Marked spirometric improvement with bronchodilators or corticosteroids 1

Management

Smoking Cessation

Smoking cessation is the single most effective intervention to alter disease progression 1:

• Reduces rapid decline in FEV1 1
• Should be the primary management tool 1
• Each health district should implement prominent anti-smoking strategies 1

Pharmacologic Treatment

Bronchodilators provide symptomatic relief despite minimal reversibility 1:

• Patients exhibit minimal but measurable bronchodilator response 1
• Airway eosinophilia is associated with better bronchodilator response 1
• Antifibrotic therapy may be considered in CPFE patients 5

Oxygen Therapy

Long-term oxygen therapy (>15 hours/day) improves survival in patients with severe resting hypoxemia 1:

• Does not benefit patients with only moderate desaturation 1
• Required in >70% of CPFE patients 5
• Continuous positive airway pressure improves survival in patients with coexistent obstructive sleep apnea 1

Surgical and Interventional Options

Lung volume reduction surgery (LVRS) improves survival in carefully selected patients 1:

• Benefits patients with upper-lobe emphysema and low post-rehabilitation exercise capacity 1
• Contraindicated in patients with FEV1 ≤20% predicted and either homogeneous emphysema or DLCO ≤20% predicted due to higher mortality 1

Bullectomy decreases dyspnea and improves function in selected patients with large bullae and preserved underlying lung 1

Lung transplantation improves health status and functional capacity but not survival 1:

• Bilateral transplantation has longer survival than single lung transplantation in patients <60 years 1

Bronchoscopic interventions (endobronchial valves, coils) show mixed results with modest improvements in 6-minute walk distance and quality of life 1

Complications and Prognosis

Pulmonary hypertension develops in 47-90% of patients and correlates with exercise desaturation 5:

• Vascular remodeling accompanies medial thickening and does not resolve with oxygen therapy 1
• Right ventricular enlargement is common in advanced disease 1

Acute exacerbations occur in 20-28% of cases 5

Lung cancer develops in 22-46% of patients, predominantly squamous cell carcinoma 5

Five-year survival is 35-55%, comparable to or worse than idiopathic pulmonary fibrosis 5

Key Clinical Pitfalls

• Do not rely on spirometry alone: Preserved FVC/TLC can mask severe emphysema, particularly in CPFE 5
• Always measure DLCO: Severely reduced DLCO (35-45% predicted) is the hallmark of emphysema and distinguishes it from asthma and chronic bronchitis 1, 5
• Recognize that symptoms may be absent: Substantial emphysema can exist without dyspnea, leading to late diagnosis 3
• Understand that emphysema begets emphysema: Most new disease arises from mechanically stressed lung adjacent to existing emphysema, not from small airway disease 6
• Screen for pulmonary hypertension: Present in up to 90% of patients and significantly impacts prognosis 5
• Maintain high suspicion for lung cancer: Occurs in nearly half of patients with emphysema 5